CHICAGO, IL – May 18, 2011 – CDG Therapeutics, Inc., (cdgti.com) today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present orally at ASCO's upcoming Annual Meeting at Chicago's McCormick Place (June 3-7, 2011) the results of its recently completed clinical Phase I human trial of a novel platform technology utilizing p28, a peptide with the potential to inhibit certain common cancers. The CDG abstract presentation is scheduled for 3 p.m. CDT on June 6, in the Arie Crown Theatre.
In the Phase I abstract, entitled "A first in class, first in human, phase I trial of p28, a non-HDM2 mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors," CDG's team of oncology specialists, in collaboration with the University of Illinois College of Medicine, describes the study in which 15 Stage IV cancer patients were enrolled in an escalating, 5 dose level Phase I trial to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics (PK/PD) of p28.
"Among the most promising aspects, at this stage of Phase I trial completion, of our cell-penetrating peptide, p28, appears to be its preferential entry to cancer cells," said Phase I abstract co-author, Tapas K. Das Gupta, M.D., Ph.D., D.Sc. "This is vital to avoiding the debilitating side effects seen in some patients receiving chemotherapy."
"We are very pleased with these clinical trial results," said David R. Volk, President and CEO of CDG Therapeutics, Inc. "The apparent lack of serious safety effects may indicate that a new and important class of drug substances will one day be available for use in the treatment of cancer."
The abstract can be viewed at cdgti.com. An audio/visual viewing of the complete oral presentation will be accessible to ASCO members and Conference attendees via the ASCO website's virtual meeting section at www.asco.org following the June 6th presentation.
About CDG
CDG Therapeutics, Inc. is a Chicago-based pharmaceutical (biotech) firm engaged in the development and commercialization of proprietary synthetic peptides originally discovered in pathogenic and nonpathogenic bacteria and green plants. As a translational drug discovery company, CDG Therapeutics owns an exclusive, worldwide license to an extensive drug platform including a pipeline of novel, first in class peptides belonging to the "smart drug" or "biologics" class, a potential $120 billion market.
Download PDF version of press release
For more information or to schedule an interview:
Contact Michael Myers at 847.208.6920, or .